Why each dollar Abbott sells now leaves it with less profit

A bigger quarter with a thinner slice

Abbott Laboratories is the Chicago healthcare group behind the FreeStyle Libre glucose sensor on diabetics' arms, Similac in the baby aisle, Ensure in the pharmacy and a long list of heart devices and diagnostic tests in hospitals. In the third quarter of 2026, July to September, it took USD 13.0bn in revenue, up 14.5% from USD 11.4bn a year earlier. The figures are for the whole group, consolidated under US accounting rules (US GAAP), in US dollars.

For a company of that size, that is a strong quarter for sales. The turn comes one line further down. Operating profit, what is left after running the business but before interest and tax, fell 34.0% to USD 1.4bn. That is USD 699m less than in the same quarter of 2025, at a time when sales rose by USD 1.6bn.

The cleanest way to see it is the operating margin, the share of each dollar of revenue that survives as operating profit. A year ago it was 18.1%. Now it is 10.4%, narrower by 7.7 pp. Put simply: Abbott used to keep roughly eighteen cents of operating profit from every dollar of sales. In this quarter it kept about ten.

Net profit followed the same road. It came in at USD 920m, down 44.0% from USD 1.6bn, and the net margin slipped from 14.5% to 7.1%. The company is plainly still profitable. It is just much less profitable per dollar than it was twelve months earlier.

Where growth usually spends its money

A margin that collapses while sales climb is rarely a mystery of the shop floor. In a business like Abbott's there are a few usual suspects, and they leave different fingerprints.

The first is price. Glucose sensors, diagnostic tests and nutrition products all sell into markets where insurers, hospital buyers and retailers negotiate hard. Growth won through discounts or cheaper reimbursement looks fine in revenue and poor in profit.

The second is cost running ahead of the sale. New factories, new sales teams and launch campaigns are paid for up front. The revenue they are meant to bring arrives later, sometimes much later.

The third, and in large healthcare groups often the biggest, is what happens when a company buys another one. The buyer adds the target's revenue, but it also adds the cost of absorbing it: integration teams, restructuring, and the write-down of the value paid for the target's patents, brands and customer relationships, which US rules spread over years as a cost. Those charges sit inside operating profit and can flatten a margin for a long time without saying anything about how well the sensors sell.

The balance sheet points in that third direction without proving it. Total assets at the end of the quarter stood at USD 108bn, against USD 84.2bn a year earlier. Equity, the owners' stake, barely moved: USD 51.0bn against USD 51.0bn, a change of 0.1%. So the company became much larger, and the extra size was not paid for by the owners. It came from lenders, from obligations to others, or from both. As a result, the equity ratio, the share of assets financed by the owners, dropped by 13.4 pp to 47.1%.

Cash went the other way. Abbott ended the quarter with USD 4.1bn, down 46.1% from USD 7.5bn. A company whose assets swell, whose equity stands still and whose cash drains has usually spent money on something big, rather than lost it in day-to-day trading.

The quarterly accounts do not split operating costs into one-off charges, amortisation of acquired assets and the running business, so they cannot settle which cause dominates here. That split is the figure that would. If most of the gap is amortisation and integration cost, the underlying business may be as healthy as before. If it sits in gross margin, Abbott is selling at worse prices than it used to.

What the thinner margin means outside Chicago

For people who wear a sensor or buy formula, a single quarter like this changes nothing on the shelf. Prices of medical products move slowly, and a group this size does not reprice because of one quarter. The pressure shows up elsewhere: in how hard the company pushes its hospital and insurer contracts next year, and in how keen it is to cut costs in the parts of the group that are not growing.

For the wider healthcare market, the pattern is a familiar one. Big device and diagnostics makers increasingly grow by buying, and the bill for that growth lands in their income statements for years after the deal. Revenue tells you how big the company has become. The margin tells you how much that size is costing.

For anyone running a business, the useful check sits right there. Take the customers, products or units you added in the past year and work out their margin on their own, separately from the rest. Include the cost of winning and absorbing them, not just the cost of serving them. Growth that was bought, whether through discounts or through an acquisition, tends to hide in exactly that slice, and a blended margin makes it look better than it is.

I would not read this quarter as a business in trouble. Abbott still earned USD 920m in three months and the owners' stake is intact. I would watch two lines in the coming quarters: whether the operating margin climbs back towards where it was, and whether cash recovers from USD 4.1bn. If both do, this was the price of getting bigger. If the margin stays near 10.4%, then the bigger Abbott is simply a less profitable one, and the sales growth was the expensive part of the story.